2023 Volume 38 Issue 2 Pages 142-147
A 77－year－old man who developed multiple nodules on his head visited a local physician, and a biopsy of one of the lesions showed cutaneous angiosarcoma. Computed tomography scan revealed numerous swollen lymph nodes extending from the left neck to the supraclavicular fossa. The patient received six doses of paclitaxel, but he developed numbness in his fingers and declined continuation of the treatment. Cancer multigene panel testing showed that the tumor mutational burden was high (31 Muts/Mb). We determined that pembrolizumab was indicated for this cutaneous angiosarcoma with a high tumor mutational burden because continuation of standard therapy was difficult. After receiving two doses of pembrolizumab (200 mg every 3 weeks), the treatment was discontinued because the patient found it difficult to frequently visit our hospital. However, 6 months after discontinuation, the tumor on his head disappeared and the lymphadenopathy in his neck continued to shrink.[Skin Cancer (Japan) 2023 ; 38 : 142－147]
